Abstract 353P
Background
Life-Sustaining Treatment Decision systems have been in effect since February 2018 in South Korea. These systems ensure that medically insignificant life-sustaining treatments, which are undesired by the patient, are avoided. This study was designed to develop and verify an explanatory model of terminal cancer patients’ intent related to decisions regarding discontinuing or not performing meaningless, life-sustaining treatments in South Korea.
Methods
Data were collected from April 15 to July 10 2019, via a survey using self-reported questionnaires. A total of 220 patients, with terminal cancer, were recruited. The hypothetical model was constructed using four exogenous variables—family function, knowledge on life-sustaining treatment decisions, likelihood of the treatment outcome, and treatment burden—and three endogenous variables—attitudes towards, the efficacy of, and intent regarding life-sustaining treatment decisions.
Results
The goodness-of-fit of this hypothetical model was x2=169.25, χ2/df=1.90, RMSEA=.07, RMR=0.02, GFI=.91, AGFI=.90, NFI=.97, CFI=.98, RMSEA=.06 The results demonstrated that knowledge on, attitudes towards, the efficacy of life-sustaining treatment decisions, and treatment burden all had significant and direct effects on participants’ intent regarding their treatment decisions. Family function was indirectly associated with participants’ intent regarding life-sustaining treatment decisions. These variables explained 88.8% of the total variance with respect to the intent regarding life-sustaining treatment decisions, with knowledge on these decisions being the most influential factor.
Conclusions
The results of this study suggest that, in order to improve terminal cancer patients’ intent regarding life-sustaining treatment decisions related to discontinuing or not performing meaningless life-sustaining treatments, nursing interventions should focus on enhancing their knowledge around this topic, as well as the efficacy of these choices. In particular, a patient’s family function is a crucial intervention strategy that can enhance their intent regarding life-sustaining treatment decisions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
205P - Treatment pattern and outcomes of radium-223 (Ra223) in metastatic castration resistant prostate cancer (mCRPC): Retrospective cohort analysis from Hong Kong
Presenter: Darren Poon
Session: Poster display session
Resources:
Abstract
206P - Population-based validation of the risk stratification among prostate cancer patients
Presenter: Mu Xie
Session: Poster display session
Resources:
Abstract
211P - Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis
Presenter: Chi Fai Ng
Session: Poster display session
Resources:
Abstract
212P - Immunotherapy with nivolumab in metastatic renal cell carcinoma patients in India: Bringing a change in clinical practice
Presenter: Amit Rauthan
Session: Poster display session
Resources:
Abstract
213P - An observational retrospective real-world study of sarcomatoid renal cell carcinoma (sRCC) patients in an Asian cancer centre
Presenter: Ravindran Kanesvaran
Session: Poster display session
Resources:
Abstract
214P - Targeting epithelial-mesenchymal transition (EMT), novel strategy to delay resistance or re-sensitize renal cancer to Sunitinib
Presenter: Revati Sharma
Session: Poster display session
Resources:
Abstract
215P - Radiologic and pathologic tumour size variation in localized renal cell carcinoma and its implications
Presenter: Shanky Singh
Session: Poster display session
Resources:
Abstract
216P - Partial versus radical nephrectomy: 10- year long-term survival among patients with Wilms tumour
Presenter: Mira Mostafa
Session: Poster display session
Resources:
Abstract
217P - Neutrophil-to-lymphocyte ratio is a useful biomarker for predicting worse clinical outcome in chemo-resistant urothelial carcinoma patients treated with pembrolizumab
Presenter: Koichiro Ogihara
Session: Poster display session
Resources:
Abstract
219P - Long-term outcomes of bladder preservation in muscle-invasive bladder cancer patients
Presenter: Amanda Dania Satiti
Session: Poster display session
Resources:
Abstract